Edgewise Therapeutics Reports Inducement Grants as permitted by the Nasdaq Listing Rules

Rhea-AI Summary

Edgewise Therapeutics (NASDAQ: EWTX), a biopharmaceutical company focused on muscle diseases, has granted equity-based inducement awards to 3 new non-executive employees. The awards include 84,250 stock options with an exercise price of $14.26 per share and 5,000 restricted stock units (RSUs).

The stock options will vest over 4 years, with 25% vesting after one year and the remainder vesting monthly. The RSUs will vest in four equal annual installments starting July 31, 2025. These awards were granted under the company's 2024 Inducement Equity Incentive Plan in compliance with Nasdaq Listing Rule 5635(c)(4).

News Market Reaction

-4.18%

1 alert

-4.18% News Effect

-$62M Valuation Impact

$1.42B Market Cap

0.8x Rel. Volume

On the day this news was published, EWTX declined 4.18%, reflecting a moderate negative market reaction. This price movement removed approximately $62M from the company's valuation, bringing the market cap to $1.42B at that time.

Data tracked by StockTitan Argus on the day of publication.

BOULDER, Colo., Aug. 6, 2025 /PRNewswire/ -- Edgewise Therapeutics, Inc. ("Edgewise" or the "Company"), (Nasdaq: EWTX), a leading muscle disease biopharmaceutical company developing novel therapeutics for muscular dystrophies and serious cardiac conditions, today announced that on July 31, 2025, Edgewise granted inducement stock options to purchase a total of 84,250 shares of Edgewise's common stock and awards of inducement restricted stock units ("RSU awards") covering a total of 5,000 shares of Edgewise's common stock to 3 new non-executive employees in connection with the commencement of their employment, pursuant to Edgewise's 2024 Inducement Equity Incentive Plan (the "Inducement Plan").

Each inducement stock option has an exercise price of $14.26 per share, which is equal to the closing price of a share of Edgewise common stock on the grant date, and shall vest as follows: 25% of the shares subject to such inducement stock option shall vest on the one year anniversary of the start date of each employee, and an additional one forty-eighth (1/48th) of the shares subject to such inducement stock option shall vest monthly thereafter, subject to the employee's continued service.

Each inducement RSU award shall vest as follows: one-fourth (1/4th) of the shares subject to each inducement RSU award shall vest on the first, second, third and fourth yearly anniversaries of July 31, 2025, subject to the employee's continued service.

Each inducement award is subject to the terms of the Inducement Plan and related forms of agreements, and were granted as inducements material to these employees to enter into employment with Edgewise in accordance with Nasdaq Listing Rule 5635(c)(4).

About Edgewise Therapeutics

Edgewise Therapeutics is a leading muscle disease biopharmaceutical company developing novel therapeutics for muscular dystrophies and serious cardiac conditions. The Company's deep expertise in muscle physiology is driving a new generation of novel therapeutics. Sevasemten is an orally administered skeletal myosin inhibitor in late-stage clinical trials in Becker and Duchenne muscular dystrophies. EDG-7500 is a novel cardiac sarcomere modulator for the treatment of hypertrophic cardiomyopathy and other diseases of diastolic dysfunction, currently in Phase 2 clinical development. The entire team at Edgewise is dedicated to our mission: changing the lives of patients and families affected by serious muscle diseases. To learn more, go to: www.edgewisetx.com or follow us on LinkedIn, X , Facebook and Instagram.

View original content to download multimedia:https://www.prnewswire.com/news-releases/edgewise-therapeutics-reports-inducement-grants-as-permitted-by-the-nasdaq-listing-rules-302523500.html

SOURCE Edgewise Therapeutics

FAQ

What inducement grants did Edgewise Therapeutics (EWTX) announce in August 2025?

Edgewise announced inducement grants of 84,250 stock options at $14.26 per share and 5,000 RSUs to three new non-executive employees.

What is the vesting schedule for EWTX's 2025 inducement stock options?

The stock options vest 25% after one year, with the remaining vesting monthly at 1/48th of shares, subject to continued employment.

How will the RSUs granted by Edgewise Therapeutics in 2025 vest?

The RSUs will vest in four equal annual installments on the yearly anniversaries of July 31, 2025, subject to continued employment.

Under what authority did Edgewise Therapeutics grant these inducement awards?

The awards were granted under the company's 2024 Inducement Equity Incentive Plan in accordance with Nasdaq Listing Rule 5635(c)(4).